Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Sep;39(3):233-42.
doi: 10.2165/00003088-200039030-00005.

Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring

C J Timmer  1 , T M Mulders
Affiliations
Clinical Trial

Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring

C J Timmer et al. Clin Pharmacokinet. 2000 Sep.

Abstract

Objective: To assess the pharmacokinetics of etonogestrel and ethinylestradiol released from a novel combined contraceptive vaginal ring (NuvaRing) releasing etonogestrel 120microg and ethinylestradiol 15 microg per day and compare them with those of a combined oral contraceptive containing desogestrel 150 microg/ethinylestradiol 30 microg (DSG/EE COC).

Design and setting: This was a nonblind, randomised, crossover study in 16 healthy women.

Methods: All volunteers received one cycle of DSG/EE COC before being randomised to 1 of 2 treatment groups. The participants in group 1 received 1 cycle of DSG/EE COC, a treatment period with NuvaRing and an intravenous bolus injection of etonogestrel/ethinylestradiol (150 microg/30 microg). Those in group 2 received a NuvaRing treatment period, 1 cycle of DSG/EE COC and the same intravenous bolus injection.

Results and conclusions: After the insertion of NuvaRing, maximum serum concentrations of etonogestrel and ethinylestradiol were achieved in approximately 1 week. The concentrations subsequently showed a gradual linear decrease in time. The maximum serum concentrations of etonogestrel and ethinylestradiol were approximately 40 and 30%, respectively, of those for the DSG/EE COC. In comparison with the DSG/EE COC, the absolute bioavailability for NuvaRing was higher for etonogestrel (102.9 vs 79.2%) and similar for ethinylestradiol (55.6 vs 53.8%). Taking the difference in daily doses into account, systemic exposure to etonogestrel was similar for NuvaRing and the DSG/EE COC, whereas systemic exposure to ethinylestradiol with NuvaRing was only approximately 50% of that for the DSG/EE COC.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hum Reprod Update. 1995 May;1(3):231-63 - PubMed
    1. Acta Obstet Gynecol Scand Suppl. 1986;134:15-20 - PubMed
    1. Am J Obstet Gynecol. 1970 May 1;107(1):100-7 - PubMed
    1. Contraception. 1986 Dec;34(6):589-602 - PubMed
    1. Contraception. 1994 Oct;50(4):301-18 - PubMed

Publication types

LinkOut - more resources